Sanofi-Aventis completes Symbion acquisition
This article was originally published in Scrip
Sanofi-Aventis has completed the A$560 million ($481 million) acquisition of Australia's Symbion Consumer from Primary Health Care. The move is expected to help the French company expand its nutraceuticals business in the Asia-Pacific region (Scrip Online, July 22nd, 2008). Symbion Consumer, part of Symbion Health, manufactures, markets and distributes nutraceuticals and other over-the-counter products throughout Australia and New Zealand. Sanofi-Aventis will consolidate Symbion Consumer sales from September 1st. Primary Health Care bought Symbion Health for more than A$2 billion in May.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.